These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 36656782)

  • 1. Nirmatrelvir Resistance in SARS-CoV-2 Omicron_BA.1 and WA1 Replicons and Escape Strategies.
    Lan S; Neilsen G; Slack RL; Cantara WA; Castaner AE; Lorson ZC; Lulkin N; Zhang H; Lee J; Cilento ME; Tedbury PR; Sarafianos SG
    bioRxiv; 2023 Jan; ():. PubMed ID: 36656782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system.
    Zhou Y; Gammeltoft KA; Ryberg LA; Pham LV; Tjørnelund HD; Binderup A; Duarte Hernandez CR; Fernandez-Antunez C; Offersgaard A; Fahnøe U; Peters GHJ; Ramirez S; Bukh J; Gottwein JM
    Sci Adv; 2022 Dec; 8(51):eadd7197. PubMed ID: 36542720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir.
    Kiso M; Furusawa Y; Uraki R; Imai M; Yamayoshi S; Kawaoka Y
    Nat Commun; 2023 Jul; 14(1):3952. PubMed ID: 37402789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Mechanism-Driven Discovery of Novel Small Molecule Inhibitors against Drug-Resistant SARS-CoV-2 M
    Yang J; Fu B; Gou R; Lin X; Wu H; Xue W
    J Chem Inf Model; 2024 Oct; 64(20):7998-8009. PubMed ID: 39387184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distal Protein-Protein Interactions Contribute to SARS-CoV-2 Main Protease Substrate Binding and Nirmatrelvir Resistance.
    Lewandowski EM; Zhang X; Tan H; Jaskolka-Brown A; Kohaal N; Frazier A; Madsen JJ; Jacobs LMC; Wang J; Chen Y
    bioRxiv; 2024 Apr; ():. PubMed ID: 38617221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Replication capacity and susceptibility of nirmatrelvir-resistant mutants to next-generation Mpro inhibitors in a SARS-CoV-2 replicon system.
    Lo CW; Kariv O; Hao C; Gammeltoft KA; Bukh J; Gottwein J; Westberg M; Lin MZ; Einav S
    Antiviral Res; 2024 Nov; 231():106022. PubMed ID: 39424074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nirmatrelvir Resistance-de Novo E166V/L50V Mutations in an Immunocompromised Patient Treated With Prolonged Nirmatrelvir/Ritonavir Monotherapy Leading to Clinical and Virological Treatment Failure-a Case Report.
    Zuckerman NS; Bucris E; Keidar-Friedman D; Amsalem M; Brosh-Nissimov T
    Clin Infect Dis; 2024 Feb; 78(2):352-355. PubMed ID: 37596935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir.
    Iketani S; Mohri H; Culbertson B; Hong SJ; Duan Y; Luck MI; Annavajhala MK; Guo Y; Sheng Z; Uhlemann AC; Goff SP; Sabo Y; Yang H; Chavez A; Ho DD
    Nature; 2023 Jan; 613(7944):558-564. PubMed ID: 36351451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir.
    Iketani S; Mohri H; Culbertson B; Hong SJ; Duan Y; Luck MI; Annavajhala MK; Guo Y; Sheng Z; Uhlemann AC; Goff SP; Sabo Y; Yang H; Chavez A; Ho DD
    bioRxiv; 2022 Aug; ():. PubMed ID: 36032976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor
    Jochmans D; Liu C; Donckers K; Stoycheva A; Boland S; Stevens SK; De Vita C; Vanmechelen B; Maes P; Trüeb B; Ebert N; Thiel V; De Jonghe S; Vangeel L; Bardiot D; Jekle A; Blatt LM; Beigelman L; Symons JA; Raboisson P; Chaltin P; Marchand A; Neyts J; Deval J; Vandyck K
    mBio; 2023 Feb; 14(1):e0281522. PubMed ID: 36625640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants.
    Greasley SE; Noell S; Plotnikova O; Ferre R; Liu W; Bolanos B; Fennell K; Nicki J; Craig T; Zhu Y; Stewart AE; Steppan CM
    J Biol Chem; 2022 Jun; 298(6):101972. PubMed ID: 35461811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic Surveillance of SARS-CoV-2 M
    Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L
    mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine.
    Kurhade C; Zou J; Xia H; Cai H; Yang Q; Cutler M; Cooper D; Muik A; Jansen KU; Xie X; Swanson KA; Shi PY
    Nat Commun; 2022 Jun; 13(1):3602. PubMed ID: 35739094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of SARS-CoV-2 3CL protease mutations on nirmatrelvir inhibitory efficiency. Computational insights into potential resistance mechanisms.
    Ramos-Guzmán CA; Andjelkovic M; Zinovjev K; Ruiz-Pernía JJ; Tuñón I
    Chem Sci; 2023 Mar; 14(10):2686-2697. PubMed ID: 36908962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of SARS-CoV-2 Main Protease Mutations at Positions L50, E166, and L167 Rendering Resistance to Covalent and Noncovalent Inhibitors.
    Kovalevsky A; Aniana A; Ghirlando R; Coates L; Drago VN; Wear L; Gerlits O; Nashed NT; Louis JM
    J Med Chem; 2024 Oct; 67(20):18478-18490. PubMed ID: 39370853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2.
    Zou J; Kurhade C; Xia H; Liu M; Xie X; Ren P; Shi PY
    Nat Commun; 2022 May; 13(1):2956. PubMed ID: 35618703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Combination of Molnupiravir with Nirmatrelvir or GC376 Has a Synergic Role in the Inhibition of SARS-CoV-2 Replication In Vitro.
    Gidari A; Sabbatini S; Schiaroli E; Bastianelli S; Pierucci S; Busti C; Comez L; Libera V; Macchiarulo A; Paciaroni A; Vicenti I; Zazzi M; Francisci D
    Microorganisms; 2022 Jul; 10(7):. PubMed ID: 35889194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mRNA bivalent booster enhances neutralization against BA.2.75.2 and BQ.1.1.
    Davis-Gardner ME; Lai L; Wali B; Samaha H; Solis D; Lee M; Porter-Morrison A; Hentenaar IT; Yamamoto F; Godbole S; Douek DC; Lee FE; Rouphael N; Moreno A; Pinsky BA; Suthar MS
    bioRxiv; 2022 Nov; ():. PubMed ID: 36380757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection.
    Kurhade C; Zou J; Xia H; Liu M; Yang Q; Cutler M; Cooper D; Muik A; Sahin U; Jansen KU; Ren P; Xie X; Swanson KA; Shi PY
    Emerg Microbes Infect; 2022 Dec; 11(1):1828-1832. PubMed ID: 35792746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the Inhibition Potency of Nirmatrelvir against Main Protease Mutants of SARS-CoV-2 Variants.
    Jiang H; Zhou Y; Zou X; Hu X; Wang J; Zeng P; Li W; Zeng X; Zhang J; Li J
    Biochemistry; 2023 Jul; 62(13):2055-2064. PubMed ID: 37222536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.